612 related articles for article (PubMed ID: 10885605)
1. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
2. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations, acetylator status, and prognosis in colorectal cancer.
Hardingham JE; Butler WJ; Roder D; Dobrovic A; Dymock RB; Sage RE; Roberts-Thomson IC
Gut; 1998 May; 42(5):669-72. PubMed ID: 9659162
[TBL] [Abstract][Full Text] [Related]
4. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
5. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival.
Dix BR; Robbins P; Soong R; Jenner D; House AK; Iacopetta BJ
Int J Cancer; 1994 Dec; 59(6):747-51. PubMed ID: 7989112
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer.
González-Aguilera JJ; Oliart S; Azcoita MM; Fernández-Peralta AM
Am J Clin Oncol; 2004 Feb; 27(1):39-45. PubMed ID: 14758132
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.
Conlin A; Smith G; Carey FA; Wolf CR; Steele RJ
Gut; 2005 Sep; 54(9):1283-6. PubMed ID: 15843421
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
[TBL] [Abstract][Full Text] [Related]
9. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases.
Russo A; Migliavacca M; Bazan V; Maturi N; Morello V; Dardanoni G; Modica G; Bazan P; Albanese I; La Farina M; Tomasino RM
Cell Prolif; 1998; 31(3-4):139-53. PubMed ID: 9853427
[TBL] [Abstract][Full Text] [Related]
12. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
15. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
[TBL] [Abstract][Full Text] [Related]
17. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.
Pan ZZ; Wan DS; Chen G; Li LR; Lu ZH; Huang BJ
World J Gastroenterol; 2004 Dec; 10(24):3688-90. PubMed ID: 15534934
[TBL] [Abstract][Full Text] [Related]
18. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
19. Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections.
Yamashita K; Yoshida T; Shinoda H; Okayasu I
Arch Pathol Lab Med; 2001 Mar; 125(3):347-52. PubMed ID: 11231481
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.
Soong R; Powell B; Elsaleh H; Gnanasampanthan G; Smith DR; Goh HS; Joseph D; Iacopetta B
Eur J Cancer; 2000 Oct; 36(16):2053-60. PubMed ID: 11044641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
